{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:36:36Z","timestamp":1788413796392,"version":"build-2803163510"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0175484","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T13:28:55Z","timestamp":1507210135000},"page":"e0175484","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status"],"prefix":"10.1371","volume":"12","author":[{"given":"Krastan B.","family":"Blagoev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Espinal-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garc\u00eda-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Alimchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Blanco-Codesido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8083-2688","authenticated-orcid":true,"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref2","first-page":"31","article-title":"Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient&apos;s bed to molecular mechanisms","volume":"1845","author":"M Buczek","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"N von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"C Hegedus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"K Takezawa","year":"2012","journal-title":"Cancer Discov"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"C Montagut","year":"2008","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"A Lievre","year":"2006","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"RG Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"CS Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","article-title":"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab","volume":"304","author":"W De Roock","year":"2010","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2012.42.2592","article-title":"Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab","volume":"30","author":"S Tejpar","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"ER Fearon","year":"1990","journal-title":"Cell"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"TS Maughan","year":"2011","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"JY Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer","volume":"32","author":"LS Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"LA Diaz Jr","year":"2012","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"T Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1634\/theoncologist.2008-0075","article-title":"Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data","volume":"13","author":"WD Stein","year":"2008","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1634\/theoncologist.2008-0016","article-title":"Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage","volume":"13","author":"WD Stein","year":"2008","journal-title":"Oncologist"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"WD Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1158\/1078-0432.CCR-11-2275","article-title":"Analyzing the pivotal trial that compared sunitinib and IFN-alpha in renal cell carcinoma, using a method that assesses tumor regression and growth","volume":"18","author":"WD Stein","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref23","article-title":"Molecular Biology of the Cell","volume":"Chapter 17","author":"Bruce Alberts","year":"2002"},{"key":"ref24","article-title":"Atlas of Clinical Nuclear Medicine","volume":"Chapter 183","author":"Ignac Fogelman","year":"2014"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1073\/pnas.0712345105","article-title":"Comparative lesion sequencing provides insights into tumor evolution","volume":"105","author":"S Jones","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0002-9440(10)65649-0","article-title":"Histopathological evaluation of apoptosis in cancer","volume":"153","author":"Y Soini","year":"1998","journal-title":"Am J Pathol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0008-6363(99)00384-3","article-title":"Morphologic and biochemical hallmarks of apoptosis","volume":"45","author":"A Saraste","year":"2000","journal-title":"Cardiovasc Res"},{"key":"ref28","first-page":"1793","article-title":"Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas","volume":"5","author":"FA Sinicrope","year":"1999","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"JM Argiles","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3465S","DOI":"10.1093\/jn\/132.11.3465S","article-title":"Dietary intake, resting energy expenditure, weight loss and survival in cancer patients","volume":"132","author":"I Bosaeus","year":"2002","journal-title":"J Nutr"},{"key":"ref31","first-page":"3347","article-title":"Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer","volume":"45","author":"WK Evans","year":"1985","journal-title":"Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1097-0142(19911001)68:7<1616::AID-CNCR2820680725>3.0.CO;2-3","article-title":"Resting energy expenditure in patients with non-small cell lung cancer","volume":"68","author":"EW Fredrix","year":"1991","journal-title":"Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000658-199404000-00001","article-title":"Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer","volume":"219","author":"JS Falconer","year":"1994","journal-title":"Ann Surg"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.1995.13.10.2600","article-title":"Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients","volume":"13","author":"AJ Staal-van den Brekel","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clnu.2009.07.001","article-title":"Resting energy expenditure and body composition in patients with newly detected cancer","volume":"29","author":"DX Cao","year":"2010","journal-title":"Clin Nutr"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<717::AID-CNCR8>3.0.CO;2-A","article-title":"Energy balance in nonsmall cell lung carcinoma patients before and after surgical resection of their tumors","volume":"79","author":"EW Fredrix","year":"1997","journal-title":"Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3945\/ajcn.2008.27273","article-title":"A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands","volume":"89","author":"JR Lieffers","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the Pathogenesis of Disease","volume":"132","author":"B Levine","year":"2008","journal-title":"Cell"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","article-title":"The Role of Autophagy in Cancer: Therapeutic Implications","volume":"10","author":"ZJ Yang","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2016.01.005","article-title":"The Evolving, Multifaceted Roles of Autophagy in Cancer","volume":"130","author":"J Liu","year":"2016","journal-title":"Adv Cancer Res"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"e0131363","DOI":"10.1371\/journal.pone.0131363","article-title":"Simultaneous inhibition of EGFR\/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells","volume":"10","author":"A Valverde","year":"2015","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0175484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T04:54:01Z","timestamp":1570164841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0175484"}},"subtitle":[],"editor":[{"given":"Jung Weon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0175484","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}